Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05589818 | Pembrolizumab for Advanced NSCLC and PS 2-3 | recruiting | Phase 2 | 45 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06364917 | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | recruiting | Phase 2 | 24 | University of Alabama at BirminghamOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT03318939 |
| Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation |
| terminated |
| Phase 2 |
| 648 |
| Spectrum Pharmaceuticals, IncINDUSTRY |
| 8 |
| Jun 12, 2026 |
| clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07358689 | Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 120 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04205552 | Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients(NEOpredict) | completed | Phase 2 | 90 | University Hospital, EssenOTHER | 3 | Jun 11, 2026 | clinicaltrials |
| NCT04984811 | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC | terminated | Phase 2 | 33 | NeoImmuneTechINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05361174 | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 53 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07641023 | Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC(DUO-NK-NSCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04332367 | Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance | recruiting | Phase 2 | 59 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05215067 | A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 44 | AkesoINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | terminated | Phase 2 | 77 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jun 9, 2026 | clinicaltrials |
| NCT07146230 | The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2(SPRINT 2) | not yet recruiting | Phase 2 | 52 | Montefiore Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07637448 | EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC | recruiting | Phase 2 | 32 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03137771 | Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 218 | NRG OncologyOTHER | 4 | Jun 8, 2026 | clinicaltrials |
| NCT03516981 | A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | completed | Phase 2 | 245 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Jun 8, 2026 | clinicaltrials |
| NCT04791839 | Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 30 | Washington University School of MedicineOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06322108 | Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008) | active not recruiting | Phase 2 | 45 | Immune Oncology Research InstituteOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | not yet recruiting | Phase 2 | 15 | Haihua YuanOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT04258033 | A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)(KUNPENG) | completed | Phase 2 | 145 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04748419 | Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab | terminated | Phase 1 / Phase 2 | 6 | University of NebraskaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07485452 | Boosting Osimertinib Blood Brain Barrier Penetration(OSIBBBOOST) | recruiting | Phase 2 | 7 | Maastricht University Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07630077 | Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05751798 | Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas | recruiting | Phase 1 / Phase 2 | 41 | OSE ImmunotherapeuticsINDUSTRY | 3 | Jun 4, 2026 | clinicaltrials |
| NCT06463665 | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer(VIRO-25) | recruiting | Phase 2 | 142 | Genelux CorporationINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07234877 | Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets | not yet recruiting | Phase 2 | 158 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Jun 4, 2026 | clinicaltrials |
| NCT07269782 | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC | recruiting | Phase 2 | 60 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07627321 | Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer(PRAD2) | not yet recruiting | Phase 2 | 39 | Anhui Provincial Cancer HospitalOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04619797 | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer(SKYSCRAPER-06) | completed | Phase 2 / Phase 3 | 542 | Hoffmann-La RocheINDUSTRY | 21 | Jun 3, 2026 | clinicaltrials |
| NCT05546476 | Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15(PROACC-1) | completed | Phase 2 | 187 | PfizerINDUSTRY | 11 | Jun 3, 2026 | clinicaltrials |
| NCT05642572 | Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | recruiting | Phase 2 | 66 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07622706 | Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma | not yet recruiting | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT06731413 | Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 40 | Virginia Commonwealth UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07619911 | SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 84 | Fudan UniversityOTHER | 0 | Jun 2, 2026 | clinicaltrials |
| NCT05633667 | Study of Novel Treatment Combinations in Patients With Lung Cancer(VELOCITY-Lung) | active not recruiting | Phase 2 | 192 | Gilead SciencesINDUSTRY | 8 | Jun 1, 2026 | clinicaltrials |
| NCT05676931 | Study With Various Immunotherapy Treatments in Participants With Lung Cancer(EDGE-Lung) | active not recruiting | Phase 2 | 400 | Gilead SciencesINDUSTRY | 10 | Jun 1, 2026 | clinicaltrials |
| NCT05933239 | Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients(MAGMA) | recruiting | Phase 2 | 20 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | GenmabINDUSTRY | 2 | Jun 1, 2026 | clinicaltrials |
| NCT06558799 | LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)(LUNAR-4) | terminated | Phase 2 | 31 | NovoCure GmbHINDUSTRY | 7 | Jun 1, 2026 | clinicaltrials |
| NCT07618793 | Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | zhang yiOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04956640 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | active not recruiting | Phase 1 / Phase 2 | 540 | Eli Lilly and CompanyINDUSTRY | 6 | May 29, 2026 | clinicaltrials |
| NCT05420220 | Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 95 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT06246110 | A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | active not recruiting | Phase 2 | 70 | Eikon TherapeuticsINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT07223047 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 252 | Bristol-Myers SquibbINDUSTRY | 3 | May 28, 2026 | clinicaltrials |
| NCT03237377 | Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | terminated | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | May 27, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT07609251 | A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing） | not yet recruiting | Phase 2 | 90 | Sinocelltech Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 15, 2026source: clinicaltrials